Leukemia

New approach to treating B-cell acute lymphoblastic leukemia shows promise

New approach to treating B-cell acute lymphoblastic leukemia shows promise

By

New compound that locks a disease-related protein into an inactive position stifled the growth of an aggressive form of leukemia.

Arthritis drug shows potential for blood cancer treatment

Arthritis drug shows potential for blood cancer treatment

By

Scientists have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers.

Preclinical data shows promise for pediatric acute lymphoblastic leukemia

Preclinical data shows promise for pediatric acute lymphoblastic leukemia

By

A recently developed drug holds great promise for some children with acute lymphoblastic leukemia (ALL).

Experimental treatment sends deadly leukemia into remission

By

An experimental new treatment approach could buy patients with a rare and dangerous leukemia type the time to obtain a stem cell transplant.

Avocados may hold the answer to beating leukemia

Avocados may hold the answer to beating leukemia

By

Can molecules derived from avocados be used as a tool to combat leukemia?

Hematologic cancer drug prices not cost-effective, may compromise patient adherence

Hematologic cancer drug prices not cost-effective, may compromise patient adherence

Majority of existing drugs for hematologic cancers are priced too high to be considered cost-effective in the United States.

Combining targeted drug with chemotherapy prolongs life for patients with B-cell lymphoma

By

The combination of ibrutinib and chemotherapy (bendamustine and rituximab [BR]) was found to reduce the risk of death by nearly 80% in patients with previously treated CLL or SLL.

Attitudes, beliefs toward end-of-life care differ between hematologic, solid tumor specialists

Attitudes, beliefs toward end-of-life care differ between hematologic, solid tumor specialists

Survey compares attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.

Breastfeeding linked to lower childhood leukemia risk

Breastfeeding linked to lower childhood leukemia risk

One more potential benefit for breastfed babies, research suggests, is a lowered risk of childhood leukemia.

Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL

Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL

By

A new meta-analysis of 26 factors has resulted in an internationally applicable prognostic index for patients with chronic lymphocytic leukemia, according to study results presented at 2015 ASCO Annual Meeting.

Targeting CD20 in chronic lymphocytic leukemia

Targeting CD20 in chronic lymphocytic leukemia

[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.

Transitioning High-Dose AML Chemo to Outpatient Setting Improves Quality of Life

Transitioning High-Dose AML Chemo to Outpatient Setting Improves Quality of Life

By

Transitioning a long-standing intensive chemotherapy regimen for acute myeloid leukemia (AML) to the outpatient setting is safe and feasible.

Researchers develop potential drug for rare leukemia

By

Researchers have developed a new drug that shows potential as a treatment for a rare type of acute leukemia, according to a recent study.

Study pinpoints genetic cause of increased leukemia risk

Study pinpoints genetic cause of increased leukemia risk

By

A mutation of the gene ETV6 has been pinpointed as the heritable, genetic cause of acute lymphoblastic leukemia (ALL), according to a study.

Promising drug offers new paradigm for treating leukemia

Promising drug offers new paradigm for treating leukemia

By

Researchers have developed a compound that delays leukemia in mice and kills leukemia cells in human tissue samples, which gives hope it could be used to improve regular leukemia therapy.

Use of pharmacokinetics to measure response in CML

Use of pharmacokinetics to measure response in CML

By

What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?

Measuring treatment response is essential to guiding leukemia treatment

Measuring treatment response is essential to guiding leukemia treatment

A measurement of the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may allow for better matching of patients to the optimal intensity of chemotherapy.

Chromosomal rearrangement is key to progress against aggressive infant leukemia

By

Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.

Childhood leukemia study reveals disease subtypes and new treatment options

Childhood leukemia study reveals disease subtypes and new treatment options

By

Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.

Breastfeeding may decrease risk of pediatric acute lymphoblastic leukemia

Breastfeeding may decrease risk of pediatric acute lymphoblastic leukemia

Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).

Presence of protein marks toxicity in leukemia

Presence of protein marks toxicity in leukemia

Presence of this protein indicates a likely toxicity effect associated with chemotherapy in acute myeloid leukemia (AML).

Gene variant increases risk and severity of nerve disorder linked to vincristine

By

Children with acute lymphoblastic leukemia with a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study.

Reasons behind ibrutinib discontinuation among patients with chronic lymphocytic leukemia

By

A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.

Genetic mutations found in leukemia increase with age

Genetic mutations found in leukemia increase with age

An increase in genetic mutations that could trigger leukemia seems to be a part of aging, according to a new study, but just having cancer-linked DNA doesn't mean the disease will develop.

New opportunity to treat drug-resistant leukemia discovered

New opportunity to treat drug-resistant leukemia discovered

By

A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipients

By

A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.

Young adult leukemia, lymphoma survivors more distressed than older survivors

Young adult leukemia, lymphoma survivors more distressed than older survivors

Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

ASCO: Chronic leukemia treatment transformation is cancer advance of the year

The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.

Test predicts response to treatment for graft-versus-host disease (GVHD)

By

A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs